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Introduction 
 Diabetes is increasingly becoming a greater threat to the overall health of the United 
States’ population.  According to the National Diabetes Statistics Report (2017) published by the 
CDC (Centers for Disease Control), it was estimated that 30.3 million people (9.4% of the total 
American population) have diabetes.1 In addition, an increase in the prevalence of diabetes is 
expected in the forthcoming years.  Type 1 diabetes accounts for approximately 5% of all cases 
of diabetes reported, while Type 2 diabetes accounts for 90 – 95% of all cases reported.1 For this 
reason, diet intervention in Type 2 diabetes will be the focus of this research paper.  The goal is 
to see if specific macronutrients in the diet are superior in Type 2 diabetes nutrition therapy by 
exploring and analyzing reviewed research regarding different macronutrient compositions in 
Type 2 diabetes diet interventions.  The conclusion will give an answer to the following 
question: “Is there an optimal macronutrient composition for diet intervention in patients with 
Type 2 diabetes?”   
What Is Covered 
 Among research articles related to Type 2 diabetes diet intervention and macronutrient 
composition, the glycemic response has been found to be a prevalent parameter that is measured 
and analyzed frequently.  In simple terms, the glycemic response is the effect food has on blood 
glucose and is induced by carbohydrate intake.2 Those with Type 2 diabetes have a hindered 
ability to regulate blood glucose adequately; therefore, overall glycemic control is significant in 
studies relating to Type 2 diabetic nutrition therapy.  Because of the emphasis placed on 
glycemic control, an abundance of research involving Type 2 diabetes nutrition therapy and 
macronutrient composition targets the comparison between carbohydrate focused diets versus 
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protein or fat focused diets.  Therefore, the following paragraphs will review research articles 
that investigated the effects different macronutrient composed diets have on individuals with 
Type 2 diabetes in relation to carbohydrate emphasized diets versus fat or protein emphasized 
diets.   
Higher Protein versus Higher Carbohydrate Diets: Sargrad Study 
 The first area of focus in relation to different macronutrient composed diets is a higher 
protein versus a higher carbohydrate diet.  The reviewed research focused on the comparison of 
these two diets in order to analyze key differences that may indicate whether one diet is superior. 
Sargrad and colleagues utilized a stratified randomization procedure to find participants for a 
study that focused on the effects of a high-protein diet (40% carbohydrate, 30% protein, 30% fat) 
versus a high-carbohydrate diet (55% carbohydrate, 15% protein, 30% fat) in 12 obese 
participants with Type 2 diabetes.  The aim was to determine if there was any superiority 
between the two diets, as well as simplifying the study criteria from a previous study in hopes of 
improving test compliance.  Compliance in Type 2 diabetes nutrition therapy is relatively low, 
with greater degrees of poorness seen with extremes in carbohydrate/protein content and as study 
duration increases.3 Over the course of two months (eight weeks), six participants (five women, 
one man) consumed the high-carbohydrate diet while the other six participants (four women, two 
men) consumed the high-protein diet.  The following parameters were measured and tracked 
throughout the eight-week study: body weight, body composition, insulin sensitivity, glycemic 
control, blood pressure, and plasma lipid levels.  
 The results revealed that both groups lost weight (-2.2+/-0.9 kg, -2.5+/-1.6 kg) with no 
significant differences between the two.  However, the high-carbohydrate group experienced a 
decrease in HbA1c (8.2% to 6.9%) and a decrease in fasting plasma glucose (8.8 to 7.2 mmol/L).  
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The high-carbohydrate group also experienced a significant increase in insulin sensitivity (12.8 
to 17.2 micromol/kg/min), which suggests that there was improvement in glycemic control.  
Interestingly, the high-protein group experienced no significant changes in the parameters 
analyzed.  However, the high-protein group saw a significant decrease in blood pressure 
(diastolic: −18±9.0 mmHg, systolic: −10.5±2.3 mmHg) while the high-carbohydrate group saw 
no significant change.  Therefore, the results derived from the Sargrad study suggested that either 
a high-protein or high-carbohydrate diet were superior in Type 2 diabetes diet intervention.3   
Larsen Study 
 Larsen and colleagues also focused on utilizing high-protein versus high-carbohydrate 
macronutrient composed diets for Type 2 diabetes nutrition therapy.  The second study was a 12-
month randomized controlled trial in which researchers compared the effects of a high-protein, 
low-fat diet (30% protein, 40% carbohydrates, 30% fat) with a high-carbohydrate, low-fat diet 
(15% protein, 55% carbohydrates, 30% fat) on glycemic control in individuals with Type 2 
diabetes.4 The purpose of the study was to see if either diet was superior in Type 2 diabetes 
nutrition therapy.  The participants in the study were classified as either overweight or obese, 
with a BMI ranging from 27 – 40 (kg/m^2).  A total of 99 individuals, from 30 to 75-years-old, 
were placed in two groups. Fifty-three individuals were placed in the high protein group while 46 
individuals were placed in the high carbohydrate group.  The following anthropometric and 
metabolic parameters were analyzed: HbA1c, weight, and glycemic control.  Parameters were 
measured at baseline and re-measured in three-month increments from the beginning of the study 
to the end point of the 12-month duration.4   
 Overall, the results revealed there were no significant differences in either of the two test 
groups with both seeing equal improvements.  Both groups saw changes in HbA1c (high-protein 
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group: -0.52% after 3 months, -0.23% after 12 months; high-carbohydrate group: -0.49% after 3 
months, -0.28% after 12 months). The changes were non-significant.  Changes in weight 
occurred in both groups (high-protein group: -2.79 kg after 3 months, -2.23kg after 12 months; 
high-carbohydrate group: -3.08 kg after 3 months, -2.17kg after 12 months).  Despite the lack of 
differences observed in both diet test groups, glycemic control improved throughout the duration 
of the study.  The results derived from the Larsen study suggested that a higher protein, low-fat 
diet is not superior to a higher carbohydrate, low-fat diet in Type 2 diabetes diet intervention.4 
Pedersen Study 
 A 12-month, parallel, randomized study conducted by Pedersen and colleagues, consisted 
of a comparison between a higher protein, lower carbohydrate diet (30% protein, 30% fat, 40% 
carbohydrate) and a standard protein, higher carbohydrate diet (20% protein, 30% fat, 50% 
carbohydrate).  This study was conducted with 45 participants (35 men, 10 women) with Type 2 
diabetes in order to see if either of the two diets were superior in Type 2 diabetes nutrition 
therapy.  Twenty-one participants were placed in the standard protein group and 24 participants 
were placed in the high-protein group.  Measurements were taken at baseline, four months, eight 
months and 12 months.  The following parameters were analyzed: fasting blood glucose, HbA1c, 
and blood pressure.5   
 The results revealed that fasting blood glucose decreased significantly at 12 months 
(high-protein diet group: −1.0 ± 0.3, standard protein diet group: −1.5 ± 0.5 mmol/L) with little 
differences seen between the two groups.  Overall, HbA1c decreased significantly in both groups 
overtime.  However, there was a significant difference found between the two groups at 6 
months (higher protein diet group −0.9%, standard protein diet group −0.3%), but this difference 
was less pronounced at 12 months (higher protein diet group −0.4%, standard protein diet group 
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−0.3%).  Blood pressure, a risk factor closely associated with the development of Type 2 
diabetes,6 was measured at baseline (higher protein diet group averaged 127/75 mmHg, standard 
protein diet group averaged 128/72 mmHg).  Blood pressure decreased slightly in the high-
protein diet group while the standard protein diet group saw no significant change (high-protein 
diet group averaged 123/72 mmHg, standard protein diet group averaged 127/75 mmHg).  The 
results derived from the Pedersen study indicated that although improvements in blood pressure 
measures were seen in both higher protein and standard protein diet groups, the higher protein 
group experienced greater improvements.  Collectively, both diet groups experienced similar 
improvements in anthropometric and metabolic parameters.5  
Limitations in Comparison of Sargrad, Larsen, and Pedersen Studies 
 Limitations were encountered during the higher protein and higher carbohydrate diet 
comparison.  Each study focused on different parameters.  However, the parameters covered in 
the analysis in this paper appeared to be consistent with the parameters emphasized in the three 
studies.  Compliance among the test participants appeared to be difficult to achieve.  The three 
studies each tested different numbers of test populations, leading to an inconsistency in number 
of participants in the three studies.  Lastly, there were different test durations among the three 
studies, which may have contributed to compromised validity in the comparison between the 
Sargrad, Larsen, and Pedersen studies.3-5 
Higher Protein versus Higher Carbohydrate Diets: Conclusion 
 The indications from Sargrad, Larsen, and Pedersen studies could not collectively 
pinpoint conclusion that there was any superiority in a higher protein diet versus a higher 
carbohydrate diet.  The final results derived from each study did not adequately concur.  Due to 
the variations of findings, there are indications of a gap in research relating to the effect 
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differences in macronutrient composition in Type 2 diabetes nutrition therapy.  However, a 
collective conclusion can be made by all three of the studies; all indicated that no matter the 
macronutrient composition in relation to a higher protein or a higher carbohydrate diet, 
improvements were made in the health of the Type 2 diabetes patients involved in the diet 
intervention tests.  This collective conclusion may indicate that there is no superiority in either a 
higher protein or higher carbohydrate diets in relation to Type 2 diabetes nutrition therapy; rather 
it is the quality of the nutrition in the diets themselves that contributes to the overall health 
improvement in nutritional treatment.3-5  
Higher Fat versus Higher Carbohydrate Diets: Brehm Study 
 The second area of focus related to different macronutrient composed diets is a higher fat 
versus a higher carbohydrate diet comparison.  The reviewed research focused on the comparison 
of these two diets in order to analyze key differences that may indicate whether one diet is 
superior.  The purpose of the study conducted by Brehm and colleagues was to compare the 
effects of a high-carbohydrate (CHO) diet to the effects of high-monounsaturated fatty acid 
(MUFA) diet in individuals with Type 2 diabetes in order to determine if one diet was superior.  
The following criteria displays both of the diets’ macronutrient compositions: high-CHO (60% 
carbohydrate, 15% protein, 25% fat) and high-MUFA (45% carbohydrate, 15% protein, and 40% 
fat) with half of the fat being MUFA.  A total of 124 overweight/obese individuals (46 men, 78 
women) with Type 2 diabetes were enrolled in the study. The participants were either in the 
high-CHO group or the high-MUFA group.  The overall retention rate for the 1-year study was 
77% (69% for the high-MUFA group, 84% for the high-CHO group).  Anthropometric and 
metabolic parameters were measured at baseline and after four, eight, and 12 months of dieting.  
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The parameters measured and analyzed included weight, total cholesterol, HDL-cholesterol, 
blood pressure, A1C (%), fasting glucose, and insulin.7   
 Results from the Brehm study revealed notable changes in anthropometric and metabolic 
parameters. Weight loss was similar in both groups over the 1-year study (high-CHO: −4.0 ± 0.8, 
high-MUFA: −3.8 ± 0.6 kg).  A similar increase in HDL-cholesterol (mg/dL) was observed in 
both groups (high-CHO: 43 ± 1.4 at baseline, 48 ± 1.4 at 12 months; high-MUFA: 42 ± 1.2 at 
baseline, 47 ± 1.3 at 12 months).  A1C (%) increased in both groups at four months (high-CHO: 
7.2 ± 0.1 at baseline, 6.8 ± 0.1 at 4 months; high-MUFA: 7.4 ± 0.1 at baseline, 6.8 ± 0.2 at 4 
months).  Interestingly, both groups increased back to nearly baseline at 12 months (high-CHO: 
6.8 ± 0.2 at 4 months, 7.2 ± 0.1 at 12 months; high-MUFA: 6.8 ± 0.2 at 4 months, 7.5 ± 0.3 at 12 
months).  Fasting glucose was taken after 10 hours of the participants’ last meal.  Similar 
improvements in fasting glucose were seen in both groups (high-CHO: 135 ± 4.7 at baseline, 127 
± 5.5 – 12 months; high-MUFA: 150 ± 7.0 at baseline, 142 ± 8.1 at 12 months).  Insulin 
(pmol/L) was improved in both groups.  However, greater improvements were observed in the 
high-MUFA group compared to the high-CHO group (high-CHO: 314 ± 37.1 at baseline, 287 ± 
26.7 at 12 months; high-MUFA 309 ± 25.4 at baseline, 251 ± 23.6 at 12 months).  At 18 months, 
researchers reviewed the parameters again.  The gathered results indicated similar improvements 
in all parameters, which indicates that either of the two diets are not superior.7  
Gaesser Study 
 Gaesser and colleagues conducted a randomized crossover study that compared the 
effects of a low-fat, high-fiber diet to and a high-fat, low-carbohydrate diet with patients with 
metabolic syndrome (factors that increase risk of heart disease, stroke, and diabetes).  Although 
this study focused on nutrition therapy for metabolic syndrome and not Type 2 diabetes, 
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metabolic syndrome is measured with similar parameters that are closely associated with Type 2 
diabetes, which makes the Gaesser study valid for the topic of this paper.8 
 The goal of the study was to specifically examine changes in insulin sensitivity and 
vascular endothelial function.  The two diets used in the study were non-calorically restricted and 
the duration of the study was four weeks.  The test population consisted of 23 women and men, 
ages 32 to 62-years-old.  All of the participants in the study were diagnosed with metabolic 
syndrome.  The Gaesser study included insulin, insulin sensitivity, and blood glucose as 
anthropometric and metabolic parameters that were measured and analyzed for four weeks.  All 
meals included consisted of the following criteria: low-fat, high-fiber (55-60% carbohydrate, 20-
25% fat, 15-20% protein, 38-48g fiber/day) and higher fat, low-carbohydrate (15-20% 
carbohydrate, 55-60% fat, 25-30% protein, 9-11g fiber/day).8 
  Results revealed similar decreases in insulin [mean (SEM), uU/ml] (low-fat, high-fiber 
diet group: 12.6 ± 1.6 at baseline, 9.9 ± 1.2 at 4 weeks; higher fat, low-carbohydrate: 11.8 ± 1.2 
at baseline, 9.8 ± 1.0 at 4 weeks).  Insulin sensitivity (QUICKI) was improved almost identically 
in both groups (low-fat, high-fiber diet group: 0.315 ± 0.006 at baseline, 0.326 ± 0.006 at 4 
weeks; higher fat, low-carbohydrate diet group: 0.315 ± 0.006 at baseline, 0.326 ± 0.007 at 4 
weeks).  Blood glucose levels (mg/dL) were reduced in the low-fat, high-fiber diet group (100.1 
± 2.4 at baseline, 96.9 ± 2.2 at 4 weeks), but no significant changes in blood glucose were seen in 
the higher fat, low-carbohydrate diet group.  In addition to the lack of significant change in blood 
glucose, the higher fat, low-carbohydrate group also experienced impaired vascular endothelial 
function compared to the low-fat, high-fiber group, which experienced no significant change.  
Therefore, the results from the Gaesser study indicated that a low-fat, high-fiber diet was 
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superior compared to a higher fat, low-carbohydrate diet for metabolic syndrome nutrition 
therapy.8 
Davis Study  
 Davis and colleagues conducted a 1-year, randomized clinical trial with the purpose of 
comparing the effects of a low-carbohydrate and a low-fat diet on weight loss and glycemic 
control in patients with Type 2 diabetes.  A total of 105 participants with Type 2 diabetes were 
enrolled in the study.  Fifty-five participants were placed in the low-carbohydrate group and 50 
were placed in the low-fat group.  The participants consumed either of the two diets for a 
duration of one year.  Quantitative measurements were taken at baseline, and then re-measured at 
three, six, and 12 months.  Parameters analyzed in the Davis study include weight, A1C (%), 
HDL-cholesterol, and blood pressure.9 
 The results revealed that weight loss occurred in both diet groups, with a greater loss seen 
in the low-carbohydrate group compared to the low-fat group (low-carbohydrate group: -13.1kg 
± 3.7 at 12 months, low-fat group: -6.5kg ± 4.9 at 12 months).  A1C (%) also decreased in both 
diet groups (low-carbohydrate group: -0.95% ± 3.2 at 12 months, low-fat group: -0.17% ± 1.2 at 
12 months).  However, the changes in A1C (%) were not significant.  HDL-cholesterol (mmol/L) 
increased significantly in both diet groups (low-carbohydrate group: 0.32 ± 0.27 at 12 months, 
low-fat group: 0.05 ± 0.21 at 12 months).  Blood pressure (mm/Hg) decreased slightly in both 
groups (low-carbohydrate group: -4.58 ± 17.5 systolic, -6.03 ± 11.4 diastolic; low-fat group: -
6.48 ± 21.1 systolic, -1.65 ± 11.3 diastolic).  The decreases in blood pressure were not 
significant.  The potential of skewed results could be attributed to the decrease in adherence, 
indicated by increases in caloric intake in both groups.  This was noted by Davis and colleagues, 
“at 6 and 12 months, there was an increase in calories and macronutrients in both groups, 
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suggesting decreased adherence.”9 Collectively, the results derived from the Davis study 
indicated that either of the two diets were not superior.9  
Limitations in Comparison of Brehm, Gaesser, and Davis Studies 
 Limitations were encountered in comparing the higher fat and higher carbohydrate diets.  
The limitations seen in the Brehm, Gaesser, and Davis studies were similar to those noted in the 
Sargrad, Larsen, and Pedersen studies.3-5,7-9 There were variations of parameters analyzed in each 
of the Brehm, Gaesser, and Davis studies.  Compliance among the test participants was a 
limitation, as well as test adherence.  Adherence was a problem in the Davis and Brehm studies, 
which lasted longer (1-year studies) than the Gaesser study (4-week study).9 Therefore, a 
variation in test duration was seen.7-9 
Higher Fat versus Higher Carbohydrate Diets: Conclusion 
 The indications from the Brehm, Gaesser, and Davis studies could not collectively come 
to conclusion that either a higher fat or a higher carbohydrate diet was superior in Type 2 
diabetes nutrition therapy.  The final results derived from each study did not adequately concur.  
Due to this inconsistency, there are indications of a gap in research relating to the effect of 
differences in macronutrient composition in Type 2 diabetes nutrition therapy.  Despite 
variations in findings, the Brehm, Gaesser, and Davis studies indicated that health improvements 
were consistently seen in the results.7-9 This collective conclusion emphasizes significance on 
nutrition quality rather than macronutrient composition in Type 2 diabetes nutrition therapy.  
Overall Conclusion 
 The goal of this paper was to see if specific macronutrient compositions in the diet are 
superior in Type 2 diabetes nutrition therapy through the process of analyzing research regarding 
this topic.  In order to gain a better understanding of the scope of knowledge individuals 
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diagnosed with diabetes had on healthy eating, a study was conducted by Castetbon and 
colleagues over dietary behavior exhibited by 45 to 74-year-old individuals diagnosed with 
diabetes.  The Castetbon study found that the individuals diagnosed with diabetes had a more 
nutritious diet than those not diagnosed, “Overall, 45 to 74-year-old adults with diabetes had a 
higher-quality diet than individuals without diabetes.”10 The results derived from the collective 
studies could not concisely pinpoint a conclusion on whether a higher protein, higher fat, or 
higher carbohydrate diet is superior in Type 2 diabetes nutrition therapy.  A consistent outcome 
in each study was the improvement of overall health in the test participants, including 
improvements in weight, HDL-cholesterol, insulin sensitivity, and A1C (%).  Improvements in 
anthropometric and metabolic parameters, as well as overall health, were achieved despite the 
variations of macronutrient composition in the diets the test participants were prescribed.3-5,7-9 In 
other words, the quantity of macronutrients consumed is not of significance related to Type 2 
diabetes nutrition therapy; instead it is the quality of the macronutrients that is significant, 
according to the reviewed studies analyzed in this paper. Therefore, there is no optimal 
macronutrient composition for diet intervention in patients with Type 2 diabetes.  Rather, the 
better diet is the one that the patient can adhere to the most in treatment, as long as the diet meets 
nutrient recommendations.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Sukowski 13 
References List 
 
1. Center for Disease Control and Prevention. National Diabetes Statistics Report – Estimates of 
diabetes and its burden in the United States. CDC. 2017 
 
2. Philip E. Cryer. Glycemic goals in diabetes: Trade-off between glycemic control and 
iotrogenic hypoglycemia. ADA. 2014; 63(7):2188-2195.  
 
3. Karin R. Sargrad, MS, RD, Carol Homko, PhD, RN, Maria Mozzoli, Guenther Boden, MD. 
Effect of high protein vs high carbohydrate intake on insulin sensitivity, body weight, 
hemoglobin A1c, and blood pressure in patients with Type 2 Diabetes Mellitus. JAND. 2005; 
105(4):573-580.  
 
4. R. N. Larsen, N. J. Mann, E. Maclean, J. E. Shaw. The effect of high-protein, low-
carbohydrate diets in the treatment of Type 2 Diabetes: A 12-month randomized controlled trial. 
Springer. 2011; 54(4):731-740.  
 
5. E. Pedersen, D. R. Jesudason, P.M. Clifton.  High protein weight loss diets in obese subjects 
with type 2 diabetes mellitus. NMCD. 2014; 24(5):554-562  
 
6. Living with Diabetes: High Blood Pressure (Hypertension). ADA. 2014 
 
7. Bonnie J. Brehm, PhD, Barbara L. Lattin, MS, Suzanne S. Summer, MS, Jane A Boback, BS, 
Gina M. Gilchrist, BS, Ronald J. Jandacek, PhD, David A D’Alessio, MD. One-year comparison 
of a high-monounsaturated fat diet with a high-carbohydrate diet in Type 2 Diabetes. ADA. Feb. 
2009; 32(2):215 – 220  
 
8. G.A. Gaesser, S. Angadi, C. Davis, C. Davis, J. Rodrigues, B. Irving, J. Patrie, A. Weltmena, 
E.J. Barrett, D. Brock. Effects of a low-fat, high-fiber diet compared with a low-carbohydrate 
diet on insulin sensitivity and endothelial function in adults with the metabolic syndrome. JAND. 
2009; 109(9):34.  
 
9. Davis NJ, Tomuta N, Schechter C, Isasi CR, Segal-Isaacson CJ, Stein D, Zonszein J, Wylie-
Rosett J. Comparative study of the effects of a 1-year dietary intervention of a low-carbohydrate 
diet versus a low-fat diet on weight and glycemic control in type 2 diabetes. ADA. 2009; 
32(7):1147-52.  
 
10. Katia Castetbon, PhD, Christophe Bonaldi, PhD, Valérie Deschamps, PhD, Michel Vernay, 
PhD, Aurélie Malon, PharmD, Benoit Salanave, PhD, Céline Druet, MD, PhD.  Diet in 45- to 74- 
year-old individuals with diagnosed diabetes: comparison to counterparts without diabetes in a 
nationally representative survey (Etude National Nutrition Santé 2006-2007). JAND. 2014; 
114(6):918 – 925. 
 
11. Marion J. Franz, MS, RDN, LDN, Jackie L. Boucher, MS, RDN, LDN, Stephanie Rutten-
Ramos, DVM, PhD, Jeffrey J. VanWormer, PhD. Lifestyle weight-loss intervention outcomes in 
  
Sukowski 14 
overweight and obese adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis of 
Randomized Clinical Trials. JAND. 2015; 115(9):1447 – 1463. 
 
 
